Castle Biosciences
Castle Biosciences Q4 Revenues Jump 53 Percent as Firm Beats Analyst Expectations
Castle also reported full-year revenues at the top end of previously issued guidance and offered full-year 2023 guidance ahead of Wall Street expectations.
Castle Biosciences Estimates 2022 Revenues in Line With Prior Projections
The company said it expects full-year revenues of at least $132 million to $137 million, with test volumes up significantly across the majority of its menu.
In Brief This Week: Biocept, Thermo Fisher, Biodesix, More
News items for the week of Nov. 21, 2022.
The company reported a record number of tests in the quarter led by its skin cancer menu but with notable sales in other test categories.
Local Coverage Determinations Roundup: Castle Bio, SkylineDx
Palmetto GBA released a final local coverage determination that covers tests from Castle Biosciences and SkylineDx.
May 9, 2022
Castle Biosciences Q1 Revenues Grow 18 Percent
Apr 5, 2022
Castle Biosciences to Acquire AltheaDx for $65M
Feb 28, 2022
Castle Biosciences Q4 Revenues Grow 45 Percent
Nov 8, 2021
Castle Biosciences Q3 Revenues Rise 54 Percent
Oct 27, 2021
Aug 9, 2021